Nxera Pharma Stock Forecast

Stock Price Forecast

According to 8 analysts polled by S&P Global, Nxera Pharma stock has a consensus rating of "Buy" and an average price target of ¥1,838. The average 1-year stock price forecast is 86.74% higher than the current stock price, while the lowest is ¥1,000 (+1.63%) and the highest is ¥4,500 (+357.32%).

Price Target: ¥1,838 (+86.74%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	¥1,000	¥1,838	¥1,350	¥4,500
Change	+1.63%	+86.74%	+37.20%	+357.32%

Analyst Ratings

The average analyst rating for Nxera Pharma stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Jan '26	Feb '26	Mar '26	Apr '26	May '26	Jun '26
Strong Buy	5	5	5	5	5	5
Buy	1	1	1	1	1	1
Hold	2	2	2	2	2	2
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	8	8	8	8	8	8

Financial Forecast

Revenue This Year

38.00B

from 29.62B

28.31%

from 29.62B

Revenue Next Year

39.63B

from 38.00B

4.30%

from 38.00B

EPS This Year

n/a

from -

EPS Next Year

n/a

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	17.71B	15.57B	12.77B	28.84B	29.62B	38.00B
Revenue Growth	100.32%	-12.10%	-18.00%	125.87%	2.71%	28.31%
Gross Profit	16.78B	14.64B	9.66B	21.22B	21.42B	31.27B
Gross Margin	94.73%	94.05%	75.70%	73.59%	72.32%	82.30%
Operating Income	6.91B	2.81B	-10.40B	-6.62B	-8.27B	5.54B
Net Income	1.02B	382.00M	-7.19B	-4.84B	-12.53B	3.83B
Free Cash Flow	8.54B	-1.37B	-11.53B	-9.25B	-2.53B	1.75B
No. Analysts	-	-	-	-	-	5

Financial currency is JPY.

Revenue Forecast

Revenue	2026	2027	2028
High	41.8B
Avg	38.0B
Low	34.9B

Revenue Growth

Revenue Growth	2026	2027	2028
High	41.1%
Avg	28.3%
Low	17.8%

EPS Forecast

EPS	2026	2027	2028
High	-
Avg	-
Low	-

EPS Growth

EPS Growth	2027	2028
High	-
Avg	-
Low	-